Mesoblast (MESO) Cash & Current Investments (2015 - 2025)
Mesoblast (MESO) posted quarterly Cash & Current Investments of $130.0 million for Q4 2025, up 241.78% year-on-year from $38.0 million in Q4 2024, and down 19.35% on a QoQ basis from $161.2 million in Q2 2025.
Mesoblast (MESO) Cash & Current Investments (2015 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Cash & Current Investments for 11 consecutive years, with $130.0 million the latest figure, recorded in Q4 2025.
- Quarterly Cash & Current Investments rose 241.78% year-over-year to $130.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $130.0 million (up 241.78% YoY) and the FY2025 annual result came in at $161.6 million, up 156.59% from the prior year.
- Cash & Current Investments retreated to $130.0 million in Q4 2025 per MESO's latest filing, from $161.2 million in the prior quarter.
- Over the last five years, Cash & Current Investments for MESO reached as high as $161.2 million in Q2 2025 and fell as low as $38.0 million in Q4 2024.
- A 5-year average of $92.4 million and a median of $77.6 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments sank 55.84% — and 2025, when it surged 241.78%.
- Year by year, Cash & Current Investments stood at $94.8 million in 2021, then dropped by 28.71% to $67.6 million in 2022, then rose by 14.69% to $77.6 million in 2023, then plunged by 50.96% to $38.0 million in 2024, then jumped by 241.78% to $130.0 million in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $130.0 million, $161.2 million, and $38.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Mesoblast | 18.88 Bn | 18.75 Bn | - | 129.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 129.98 Mn |
| Jun 30, 2025 | 161.16 Mn |
| Dec 31, 2024 | 38.03 Mn |
| Jun 30, 2024 | 62.96 Mn |
| Dec 31, 2023 | 77.55 Mn |
| Jun 30, 2023 | 71.32 Mn |
| Mar 31, 2023 | 48.80 Mn |
| Dec 31, 2022 | 67.62 Mn |
| Sep 30, 2022 | 85.50 Mn |
| Jun 30, 2022 | 60.45 Mn |
| Mar 31, 2022 | 76.76 Mn |
| Dec 31, 2021 | 94.85 Mn |
| Sep 30, 2021 | 115.96 Mn |
| Jun 30, 2021 | 136.88 Mn |
| Mar 31, 2021 | 158.26 Mn |
| Dec 31, 2020 | 77.53 Mn |
| Sep 30, 2020 | 108.12 Mn |
| Jun 30, 2020 | 129.33 Mn |
| Mar 31, 2020 | 60.08 Mn |
| Dec 31, 2019 | 81.35 Mn |